Janumet (Metformin Hydrochloride, Sitagliptin)

Metformin belongs to the biguanide class and primarily reduces hepatic gluconeogenesis while increasing peripheral insulin sensitivity, leading to lower glucose output from the liver. Sitagliptin is a selective dipeptidyl‑peptidase‑4 (DPP‑4) inhibitor; it prevents the breakdown of endogenous incretin hormones, thereby enhancing glucose‑dependent insulin release and suppressing glucagon after meals. Together they provide complementary mechanisms to control blood sugar.

The specific dose of Janumet is determined by the prescribing healthcare professional based on individual factors such as current glycemic control, renal function, and concomitant medications. The prescriber selects the appropriate tablet strength and dosing schedule, which is typically taken once daily with meals. Patients should follow the exact instructions provided on the prescription label.

Safety of Janumet in pregnancy and lactation has not been fully established. Metformin is sometimes continued during pregnancy under specialist supervision, whereas sitagliptin lacks sufficient data. The drug should only be used during pregnancy or while breastfeeding if the potential benefits outweigh the potential risks, and this decision must be made by a qualified healthcare provider.

To request Janumet, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation. The team then confirms pricing, availability, shipping terms (including any temperature requirements), and assists with import documentation.

Janumet offers a fixed‑dose combination of metformin and sitagliptin, providing both insulin‑sensitising and incretin‑based mechanisms in a single tablet. Compared with metformin alone, it adds greater post‑prandial glucose reduction. Relative to sulfonylureas, it carries a lower risk of hypoglycaemia. Compared with other DPP‑4 inhibitors, the efficacy is similar, but the combination simplifies therapy by reducing pill burden.

Janumet tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged. No refrigeration is required for this oral tablet formulation.

Janumet is taken orally, usually once daily with the main meal to improve gastrointestinal tolerance. The tablet should be swallowed whole with a sufficient amount of water and not crushed or chewed. Patients should adhere to the dosing schedule prescribed by their clinician and continue to follow dietary and exercise recommendations for optimal glycaemic control.

The most serious adverse reactions to Janumet include lactic acidosis, a rare but potentially fatal condition linked to metformin, especially in patients with renal impairment or severe infection. Other critical risks are severe hypoglycaemia when combined with insulin or sulfonylureas, pancreatitis, and allergic reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these symptoms occur.

Janumet is contraindicated in patients with known hypersensitivity to metformin, sitagliptin, or any component of the tablet. It should also be avoided in individuals with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in patients with hepatic disease that predisposes to lactic acidosis. Clinicians must assess these conditions before prescribing.